» Articles » PMID: 24355322

Laparoscopic Sleeve Gastrectomy in Patients with NASH-related Cirrhosis: a Case-matched Study

Overview
Publisher Elsevier
Specialty Endocrinology
Date 2013 Dec 21
PMID 24355322
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Laparoscopic sleeve gastrectomy (SG) is a validated procedure for the surgical treatment of morbid obesity. Cirrhosis is often considered a relative contraindication to elective extrahepatic surgery. The objective of this study was to evaluate the morbidity related to SG performed in cirrhotic patients compared with noncirrhotic patients.

Methods: Between March 2004 and January 2013, we included all patients with cirrhosis undergoing SG (13 patients). These patients (SG-cirrhosis group) were matched in terms of preoperative data (age, gender, body mass index, and co-morbidities) on a 1:2 basis, with 26 noncirrhotic patients (SG group) selected from a population of 750 patients. Cirrhosis was diagnosed postoperatively on histologic exam. The primary endpoint was the overall postoperative complication rate. Secondary endpoints were operating time, revisional surgery rate, gastric fistula and bleeding rates, postoperative mortality, and weight loss over a 24-month period.

Results: The SG-cirrhosis group consisted of 13 patients with a median age of 52 years. All patients in the SG-cirrhosis group were Child A. Etiology of cirrhosis was related to NASH in 93.3%. Median operating time in the SG-cirrhosis group and SG group was 75 minutes versus 80 minutes (P = .59). No postoperative mortality was observed in either group. The overall postoperative complication rate was 7.7% versus 7.7% (P = 1). The major complication rate was 0% versus 7.7% (P = .22), and the postoperative gastric fistula rate was 0% versus 3.8% (P = .47). No complications related to cirrhosis were reported.

Conclusion: SG can be performed in Child A cirrhosis with no increased risk of postoperative complications and no specific complications related to cirrhosis. Weight loss for patients with cirrhosis undergoing SG is similar to that observed in noncirrhotic patients.

Citing Articles

Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Bridge to Bariatric Surgery in Morbidly Obese Patients with Cirrhosis and Clinically Significant Portal Hypertension.

Pais R, Chouik Y, Moga L, Lebedel L, Silvain C, Genser L Obes Surg. 2024; 35(2):395-405.

PMID: 39739182 DOI: 10.1007/s11695-024-07583-w.


Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.

Alqahtan S, Brown R Gastroenterol Hepatol (N Y). 2023; 19(1):20-29.

PMID: 36865816 PMC: 9972654.


Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?.

Mandour M, El-Hassan M, Elkomi R, Oben J World J Hepatol. 2022; 14(9):1704-1717.

PMID: 36185721 PMC: 9521460. DOI: 10.4254/wjh.v14.i9.1704.


Bariatric surgery, obesity and liver transplantation.

Ahmed Z, Khan M, Vazquez-Montesino L, Ahmed A Transl Gastroenterol Hepatol. 2022; 7:25.

PMID: 35892056 PMC: 9257534. DOI: 10.21037/tgh-2020-14.


Current treatment of non-alcoholic fatty liver disease.

Paternostro R, Trauner M J Intern Med. 2022; 292(2):190-204.

PMID: 35796150 PMC: 9546342. DOI: 10.1111/joim.13531.